Target intelligence / Profile preview

Protein IpaC (Invasin plasmid antigen C) (IpaC)

Target
IpaC
Molecular classification
Bacterial virulence factor, Type III secretion system translocator, Effector protein
01

Overview

Protein IpaC, also known as Invasin plasmid antigen C, is a critical virulence factor produced by Shigella species, the causative agents of bacillary dysentery (UniProt P0A223). It is a key component of the Type III Secretion System (T3SS), specifically acting as a translocator protein that forms a translocon pore in the host cell membrane alongside IpaB (PubMed: 11443086). This pore allows the injection of bacterial effector proteins directly into the host cytoplasm, which is essential for the infection process. Additionally, IpaC plays a direct role in inducing host cell actin polymerization and membrane ruffling by activating Src-family kinases and Rho GTPases, which facilitates the internalization of the bacteria (PubMed: 15280483). Because it is essential for virulence and highly conserved among Shigella strains, IpaC is a primary target for the development of subunit vaccines, such as Invaplex, and anti-virulence drugs designed to block bacterial entry into intestinal epithelial cells (PubMed: 25691591). Experimental small molecules and antibodies targeting IpaC aim to disrupt the T3SS machinery or neutralize the protein's ability to manipulate host cell signaling.

Other names
Invasin plasmid antigen CIpaC proteinShigella invasin CTranslocator protein IpaC
02

Mechanism of action

Inhibition of the Type III secretion system (T3SS) translocon formation or neutralization of the protein's ability to induce host cell membrane remodeling.

03

Biological functions

Host cell invasionMembrane pore formationActin polymerization inductionProtein translocationInduction of macropinocytosis
04

Disease associations

ShigellosisBacillary dysenteryInfection
05

Safety considerations

Potential for low cross-reactivity with host proteinsRequirement for mucosal delivery for vaccinesRisk of incomplete protection across all serotypes
06

Interacting drugs

Invaplex (vaccine candidate)

2 more in the full profile.

07

Biomarkers

Anti-IpaC IgG antibodiesAnti-IpaC IgA antibodiesIpaC antigen detection

Beyond the preview

Go deeper on Protein IpaC (Invasin plasmid antigen C) (IpaC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein IpaC (Invasin plasmid antigen C) (IpaC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call